Related Experiment Videos
Cyclooxygenase-2 and gastric carcinogenesis
Kirsi Saukkonen1, Johanna Rintahaka, Anna Sivula
1Department of Pathology, Helsinki University, Central Hospital, Helsinki, Finland.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|November 18, 2003
Summary
Nonsteroid anti-inflammatory drugs (NSAIDs) show promise in reducing gastric cancer risk. Targeting cyclooxygenase-2 (Cox-2) with inhibitors like celecoxib may offer new therapeutic strategies for stomach neoplasias.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Epidemiological studies link NSAID use to reduced gastric cancer risk.
- Cyclooxygenase-2 (Cox-2) is implicated in gastric carcinogenesis and elevated in gastric adenocarcinomas.
- Cox-2 expression correlates with advanced disease, suggesting a role in tumor progression.
Purpose of the Study:
- To investigate the role of Cox-2 in gastric carcinogenesis.
- To evaluate the therapeutic potential of Cox-2 inhibitors in gastric neoplasias.
Main Methods:
- Analysis of Cox-2 expression in gastric adenocarcinomas and precursor lesions.
- Studies in trefoil factor 1 deficient mice with gastric adenomas.
- Treatment of mice with the Cox-2 selective inhibitor, celecoxib.
Main Results:
- Elevated Cox-2 expression observed in gastric adenocarcinomas, correlating with invasion and metastasis.
- Cox-2 is present in preinvasive lesions, indicating early involvement in carcinogenesis.
- Celecoxib treatment reduced adenoma size in a mouse model.
Conclusions:
- Cox-2 derived prostanoids may drive aggressive gastric adenocarcinoma behavior.
- Cox-2 inhibitors show potential as chemotherapeutic or adjuvant agents for gastric neoplasias.
- Clinical studies investigating Cox-2 inhibitors for gastric cancer are warranted.